System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

David Capper is an expert in Neurology at Charité - University Medicine Berlin (Germany). As of October 2026, ScienceLeadR ranks David Capper in the top 1% of experts worldwide for Brain Neoplasms, Nervous System Neoplasms and Glioma. David Capper has authored 521 publications, the most recent in 2026, and is an investigator in 9 clinical trials, 1 of them ongoing. SLR score: 1,703 (community average: 125). How the SLR is computed.

LeadR Profile

David Capper Charité - University Medicine Berlin Germany
1 703 ScienceLeadR Reputation 1703

Unlock

Register Login
Network Map

Neurology

Subspecialties: Oncology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2009 - 2026
Source: PubMed

Heidelberg University (Germany)

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 521

Citations

Citations: 37 875 1st author: 19 Last author: 28 Unique author: 1

Main journals

Neuro Oncol 122
Acta Neuropathol 73
Brain Pathol 26
Neuropathol Appl Neurobiol 20
Cancer Res 12

Best Journals

Nature 4
Cancer Discov 3
Cell 3

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Age-associated epigenomic heterogeneity in papillary tumors of the pineal region: a multicenter YoungNOA investigation.
PMID 42665813 — epigenomics, neoplasms, nervous system diseases		Acta Neuropathol Commun20260
Exploring the landscape of targetable alterations in patients with glioblastoma.
PMID 42618642 — cells, pharmaceutical preparations, brain, glioblastoma, therapeutics		Nat Rev Clin Oncol Top journal20260
Sellar region neurocytomas exhibit a CIMP and neuroendocrine-like epigenetic signature distinct from other intra-axial neurocytomas.
PMID 42611353 — cells, neoplasms, pathology, phenotype, neurocytoma, cluster analysis, neurology		Acta Neuropathol20260
Time-dependent prognostic value of automated Ki67 assessment and its integration with molecular risk profiling in WHO grade 2 meningioma.
PMID 42522047 — meningioma, nervous system diseases		Acta Neuropathol Commun20260
DNA methylation profiling enables subclassification of mucinous ovarian carcinoma and distinguishes it from extraovarian mucinous metastases.
PMID 42508406 — biological science disciplines, ovary, neoplasms, machine learning, dna methylation, neoplasm metastasis, ovarian neoplasms, dna		Cell Rep Med20260

Clinical Studies 9

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 2 5
Phase 3 2
N/A 1
Phase 1/Phase 2 1

By status:

Completed 5
Active not recruiting 2
Recruiting 1
Unknown 1

By type:

Interventional 8
Observational 1

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 0
multicentric5to9 0
multicentricup10 6

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
DAY101 vs Standard of Care Chemotherapy in Pediatric Participants With Low Grade Glioma Requiring First Line Systemic Therapy (LOGGIC FIREFLY 2)
NCT05566795 — injections, glioma, powders, suspensions, noonan syndrome, fibrosarcoma, antineoplastic agents, neoplasms, tablets, drug therapy, solutions, therapeutics, carboplatin, chemotherapy		Phase 3Active not recruiting2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS